Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SGK1 | O00141 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | CDC25A | P30304 | 1/20 | 0.41 |
| ▸ | CDC25B | P30305 | 1/20 | 0.41 |
| ▸ | CDC25C | P30307 | 1/20 | 0.41 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13928711 | 0.90 | RAB9A (0.46) | L3MBTL1RAB9AALDH1A1NPC1MEN1 | |
| Hydrochloric Acid SCHEMBL6172861 | 0.89 | RAB9A (0.44) | L3MBTL1RAB9AALDH1A1NPC1MEN1 | |
| SCHEMBL6174153 | 0.84 | RAB9A (0.41) | L3MBTL1RAB9AALDH1A1NPC1MEN1 | |
| Hydrochloric Acid SCHEMBL6173977 | 0.78 | KMT2A (0.54) | L3MBTL1RAB9AALDH1A1NPC1MEN1 | |
| Hydrochloric Acid SCHEMBL6174678 | 0.78 | KMT2A (0.48) | L3MBTL1RAB9AALDH1A1NPC1MEN1 | |
| Hydrochloric Acid SCHEMBL6171897 | 0.78 | KMT2A (0.48) | L3MBTL1RAB9AALDH1A1NPC1MEN1 | |
| Hydrochloric Acid SCHEMBL6177018 | 0.78 | RAB9A (0.50) | L3MBTL1RAB9AALDH1A1NPC1MEN1 | |
| SCHEMBL6172818 | 0.77 | KMT2A (0.48) | L3MBTL1RAB9AALDH1A1NPC1MEN1 | |
| SCHEMBL6172087 | 0.77 | KMT2A (0.47) | L3MBTL1RAB9AALDH1A1NPC1MEN1 | |
| SCHEMBL6173123 | 0.73 | RAB9A (0.61) | L3MBTL1RAB9AALDH1A1NPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949543-B2 | Amide derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-27 | — | — | US | claimed |
| EP-1340750-B1 | AMIDE DERIVATIVES | YAMANOUCHI PHARMA CO LTD (JP) | 2005-08-17 | — | — | EP | claimed |
| US-20040034232-A1 | Amide derivative | ASTELLAS PHARMA INC. (JP) | 2004-02-19 | — | — | US | claimed |
| EP-1340750-A1 | AMIDE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-09-03 | — | — | EP | claimed |
| US-20090048310-A1 | AGENT FOR PREVENTION/TREATMENT OF DISEASE CAUSED BY ACYCLOVIR-RESISTANT HERPESVIRUS | ASTELLAS PHARMA INC. (JP) | 2009-02-19 | — | — | US | disclosed |
| US-20090048310-A1 | AGENT FOR PREVENTION/TREATMENT OF DISEASE CAUSED BY ACYCLOVIR-RESISTANT HERPESVIRUS | ASTELLAS PHARMA INC. (JP) | 2009-02-19 | — | — | US | disclosed |
| US-7465748-B2 | Antiherpesvirus drugs; great pharmacokinetics, good antivirus activity when administered orally at a low dose, high safety profile, less mutagenic concerns; N-(2,6-dimethylphenyl)-N-(2-{[4-(1,3-oxazol-4-yl)phenyl]amino)-2-oxoethyl)tetrahydro-2H-thiopyran-4-carboxamide 1,1-dioxide | ASTELLAS PHARMA INC. (JP) | 2008-12-16 | — | — | US | disclosed |
| US-7465748-B2 | Antiherpesvirus drugs; great pharmacokinetics, good antivirus activity when administered orally at a low dose, high safety profile, less mutagenic concerns; N-(2,6-dimethylphenyl)-N-(2-{[4-(1,3-oxazol-4-yl)phenyl]amino)-2-oxoethyl)tetrahydro-2H-thiopyran-4-carboxamide 1,1-dioxide | ASTELLAS PHARMA INC. (JP) | 2008-12-16 | — | — | US | disclosed |
| US-6949543-B2 | Amide derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-27 | — | — | US | disclosed |
| EP-1340750-B1 | AMIDE DERIVATIVES | YAMANOUCHI PHARMA CO LTD (JP) | 2005-08-17 | — | — | EP | disclosed |
| US-20040034232-A1 | Amide derivative | ASTELLAS PHARMA INC. (JP) | 2004-02-19 | — | — | US | disclosed |
| EP-1340750-A1 | AMIDE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048310-A1 | AGENT FOR PREVENTION/TREATMENT OF DISEASE CAUSED BY ACYCLOVIR-RESISTANT HERPESVIRUS | ZC3HAV1, ZC3HAV1L, GRIK2 | L3MBTL1 206/4885RAB9A 1654/4885ALDH1A1 4318/4885 |
| US-20040034232-A1 | Amide derivative | HDAC2, ZC3HAV1, HDAC4 | L3MBTL1 1744/4885RAB9A 1475/4885ALDH1A1 3774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.